Investment Summary |
|
|---|---|
| Date | 2023-03-01 |
| Target | Wilson Wolf |
| Sector | Life Science |
| Investor(s) | Bio-Techne |
| Deal Type | Stake Purchase |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1976 |
| Sector | Life Science |
| Employees | 3,200 |
| Revenue | 1.2B USD (2024) |
Bio-Techne is a life sciences company that provides bioactive tools and resources for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. Bio-Techne was founded in 1976 and is based in Minneapolis, Minnesota.
| DEAL STATS | # |
|---|---|
| Overall | 17 of 18 |
| Sector: Life Science M&A | 10 of 11 |
| Type: Stake Purchase M&A Deals | 1 of 1 |
| State: Minnesota M&A | 2 of 2 |
| Country: United States M&A | 15 of 15 |
| Year: 2023 M&A | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-06-22 |
Namocell
Mountain View, California, United States Namocell is a provider of fast and easy-to-use single-cell sorting and dispensing platforms that are gentle to cells, and preserve cell viability and integrity. Single cell selection and sorting is a critical technology in various workflows in both biotherapeutics and diagnostics, including cell and gene therapy development and commercialization, cell engineering, cell line development, single-cell genomics, antibody discovery, synthetic biology, and rare cell isolation. Namocell was formed in 2014 and is based in Mountain View, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-06-22 |
Lunaphore
Tolochenaz, Switzerland Lunaphore is a developer of fully automated spatial biology solutions using precision microfluidic technology capable of revealing hyperplex proteomic and transcriptomic biomarkers in tumors and other tissues at single-cell and subcellular resolution. The company's technology and instrumentation empower researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and accelerate therapeutic development. Its spatial biology technology enables the identification of biomarker "signatures" with clinical relevance, providing data necessary to support the development of diagnostic tools and streamline clinical trials, and ultimately improve patient outcomes. Lunaphore was formed in 2014 and is based in Tolochenaz, Switzerland. |
Buy | - |
